Current advances in antitubercular drug discovery: potent prototypes and new targets


Autoria(s): Fernandes, Guilherme Felipe dos Santos; Jornada, Daniela Hartmann; Souza, Paula Carolina de; Chin, Chung Man; Pavan, Fernando Rogerio; Santos, Jean Leandro dos
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

07/12/2015

07/12/2015

2015

Resumo

Tuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values < 7 µM, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery.

Formato

3133-3161

Identificador

http://dx.doi.org/10.2174/0929867322666150818103836#sthash.EOREFJmy.dpuf

Current Medicinal Chemistry, v. 22, n. 27, p. 3133-3161, 2015.

1875-533X

http://hdl.handle.net/11449/131461

10.2174/0929867322666150818103836#sthash.EOREFJmy.dpuf

26282941

Idioma(s)

eng

Publicador

Bentham Science Publishers

Relação

Current Medicinal Chemistry

Direitos

closedAccess

Palavras-Chave #Antitubercular drugs #Drug discovery #Mycobacterium tuberculosis #Resistant tuberculosis #Tuberculosis #Tuberculosis targets
Tipo

info:eu-repo/semantics/article